Method of the administration of drugs with binding affinity for plasma protein and preparation to be used in the method

Abstract

A method of the administration of drugs with binding affinity for plasma protein and drugs regulating the effective ingredient dose of drugs with binding affinity for plasma protein; and a preparation whereby the effective ingredient dose of drugs with binding affinity for plasma protein is regulated. The above administration method is characterized in that, in the administration of a first drug having binding affinity for plasma protein, a second drug having binding affinity for the same plasma protein is administered simultaneously with the first drug or before or after the administration of the first drug to thereby regulate the binding of the first drug to the plasma protein.

1 . Method of in vivo administration of drugs with binding affinity for plasma protein, which is characterized in that, in the administration of a first drug with binding affinity for plasma protein, a single or plural second drug with binding affinity for the same plasma protein for which the first drug has binding affinity, is administered simultaneously with the first drug or before or after the administration of the first drug to thereby regulate the binding of the first drug to the plasma protein.  
   
   
       2 . The method of the administration of drugs with binding affinity for plasma protein according to  claim 1 , wherein the second drug has binding affinity to the same binding sites on plasma protein to which the first drug has binding affinity.  
   
   
       3 . The method of the administration of drug with binding affinity for plasma protein according to  claim 1 , wherein the first drug is a radiodiagnostic drug for in vivo use or a radiotherapeutic drug for in vivo use.  
   
   
       4 . The method of the administration of drugs with binding affinity for plasma protein according to  claim 2 , wherein the first drug is a radiodiagnostic drug for in vivo use or a radiotherapeutic drug for in vivo use.  
   
   
       5 . The method of the administration of drugs with binding affinity for plasma protein according to  claim 3  or  4 , wherein the radiodiagnostic drug for in vivo use or the radiotherapeutic drug for in vivo use is radiolabeled with one nuclide selected from the group consisting of 11-carbon ( 11 C), 15-oxygen ( 15 O), 18-fluorine ( 18 F), 32-phosphorus ( 32 p), 59-iron ( 59 Fe), 67-copper ( 67 Cu) , 67-gallium ( 67 Ga), 81m-krypton ( 81m Kr), 81-rubidium ( 81 Rb), 89-strontium ( 89 Sr), 90-yttrium ( 90 Y), 99m-technetium ( 99m Tc), 111-indium ( 111 In), 123-iodine ( 123 I), 125-iodine ( 125 I), 131-iodine ( 131 I), 133-xenon ( 133 Xe), 117m-tin ( 117m Sn), 153-samarium ( 153 Sm), 186-rhenium ( 186 Re), 188-rhenium ( 188 Re), 201-thallium ( 201 T1), 212-bismuth ( 212 Bi), 213-bismuth ( 213 Bi) and 211-astatine ( 211 At).  
   
   
       6 . The method of the administration of drugs with binding affinity for plasma protein according to  claim 3  or  4 , wherein the first drug has one group labeled with nuclide and the group is selected from the group consisting of a bisaminothiol compound, a monaminomonoamidobisthiol compound, a bisamidobisthiol compound, a mercaptoacetylglycylglycylglycine compound, a hexamethylpropyleneamineoxime compound, an ethylenebis [bis(2-ethoxyethyl) phosphine] compound, a 2,3-dimercaptosuccinic acid compound, an ethylenecysteine dimer compound, a methoxyisobutylisonitrile compound, a polyamine compound, a pyriodoxylydeneaminate compound, methylene diphosphonate, a hydroxymethylene diphosphonate compound, a β-methyl-ω-phenylpentadecanoic acid compound, N-isopropylamphetamine, hippuric acid, benzylguanidine and a tropane compound.  
   
   
       7 . The method of the administration of drugs with binding affinity for plasma protein according to any one of claims  1  to 4, wherein the single or plural second drug is selected from the group consisting of bucolome, cefazolin, etoposide, phenylbutazone, aspirine, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, and disopyramide.  
   
   
       8 . A pharmaceutical preparation for regulating binding affinity of a first drug for plasma protein, which comprises a first drug with binding affinity for plasma protein and a single or plural second drug with binding affinity for the same plasma protein, for which the first drug has binding affinity.  
   
   
       9 . The pharmaceutical preparation according to  claim 8 , wherein each of the first drug and the second drug is in a separate container, and prepared as a kit.  
   
   
       10 . The pharmaceutical preparation according to  claim 8 , wherein the second drug has binding affinity to the same binding sites on the plasma protein, to which the first drug has binding affinity.  
   
   
       11 . The pharmaceutical preparation according to  claim 9 , wherein the second drug has binding affinity to the same binding sites on the plasma protein, to which the first drug has binding affinity.  
   
   
       12 . The pharmaceutical preparation according to any one of  claims 8  to  11 , wherein the first drug is a radiodiagnostic drug for in vivo use or a radiotherapeutic drug for in vivo use.  
   
   
       13 . The pharmaceutical preparation according to  claim 12 , wherein the radiodiagnostic drug for in vivo use or the radiotherapeutic drug for in vivo use is radiolabeled with one nuclide selected from the group consisting of 11-carbon ( 11 C), 15-oxygen ( 15 O), 18-fluorine ( 18 F), 32-phosphorus ( 32 p), 59-iron ( 59 Fe), 67-copper ( 67 Cu), 67-gallium ( 67 Ga), 81m-krypton ( 81m Kr), 81-rubidium ( 81 Rb), 89-strontium ( 89 Sr), 90-yttrium ( 90 Y), 99m-technetium ( 99m Tc), 111-indium ( 111 In), 123-iodine ( 123 I), 125-iodine ( 125 I), 131-iodine ( 131 I), 133-xenon ( 133 Xe), 117m-tin ( 117m Sn), 153-samarium ( 153 Sm), 186-rhenium ( 186  Re), 188-rhenium ( 188 Re), 201-thallium ( 201 T 1 ), 212-bismuth ( 212 Bi), 213-bismuth ( 213 Bi) and 211-astatine ( 211 At).  
   
   
       14 . The pharmaceutical preparation according to  claim 12 , wherein the first drug has one group labeled with nuclide and the group is selected from the group consisting of a bisaminothiol compound, a monaminomonoamidobisthiol compound, a bisamidobisthiol compound, a mercaptoacetylglycylglycylglycine compound, a hexamethylpropyleneamineoxime compound, an ethylenebis [bis(2-ethoxyethyl) phosphine] compound, a 2,3-dimercaptosuccinic acid compound, an ethylenecysteine dimer compound, a methoxyisobutylisonitrile compound, a polyamine compound, a pyriodoxylydeneaminate compound, methylene diphosphonate, a hydroxymethylene diphosphonate compound, a β-methyl-ω-phenylpentadecanoic acid compound, N-isopropylamphetamine, hippuric acid, benzylguanidine and a tropane compound.  
   
   
       15 . The pharmaceutical preparation according to any one of  claims 8  to  11 , wherein the single or plural second drug is selected from the group consisting of bucolome, cefazolin, etoposide, phenylbutazone, aspirine, salicylic acid, ceftriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-2-naphthylacetic acid, ibuprofen, probenecid, dansyl-L-asparagine, and disopyramide.  
   
   
       16 . The pharmaceutical preparation according to  claim 12 , wherein the single or plural second drug is selected from the group consisting of bucolome, cefazoline, etoposide, phenylbutazone, aspirine, salicylic acid, ceftriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-2-naphthylacetic acid, ibuprofen, probenecid, dansyl-L-asparagine, and disopyramide.